XML 65 R20.htm IDEA: XBRL DOCUMENT
v3.23.3

Liability Related to the Sale of Future Royalties | 12 Months Ended
--- | ---
Sep. 30, 2023
Liability Related To The Sale Of Future Royalties [Abstract] |
Liability Related to the Sale of Future Royalties | LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0 million in cash to the Company in consideration for the Company’s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0 million upon Royalty Pharma’s receipt of at least $70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0 million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate periodically based on its current revenue forecasts utilizing the prospective method. For 2023, the Company recognized non-cash interest expense of $18.3 million, on the consolidated statements of operations and comprehensive loss.

X
- Definition Liability Related To The Sale Of Future Royalties + References No definition available. + Details
Name: | arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract
Namespace Prefix: | arwr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability Related To The Sale Of Future Royalties + References No definition available. + Details
Name: | arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock
Namespace Prefix: | arwr_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration